Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Ian M. Fearon"'
Autor:
Milly N. Kanobe, Gary M. Dull, John Darnell, Tao Jin, Buddy Brown, Jeff Coffield, Brian M. Keyser, Ian M. Fearon, Patrudu Makena, Sarah A. Baxter, Kristen G. Jordan
Publikováno v:
Environmental Advances, Vol 17, Iss , Pp 100580- (2024)
Compared to cigarette smoke, heated tobacco product (HTP) aerosol contains significantly fewer and lower levels of harmful and potentially harmful constituents (HPHCs). However, the impact on environmental air is relatively unexplored. Therefore, thi
Externí odkaz:
https://doaj.org/article/5bfa3d4350d944ff95c297c36938cb67
Autor:
Simon McDermott, Kerstin Reichmann, Elizabeth Mason, Ian M. Fearon, Grant O’Connell, Thomas Nahde
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract Nicotine delivery and subjective effects are determinants of the ability of potentially less harmful tobacco products such as heated tobacco products (HTPs) to support adult smokers in switching away from cigarettes, and therefore to support
Externí odkaz:
https://doaj.org/article/b4dd3b5d254b46c0bf0c7f29ccb2394a
Publikováno v:
Harm Reduction Journal, Vol 19, Iss 1, Pp 1-12 (2022)
Abstract Background Nicotine pharmacokinetic assessments of electronic nicotine delivery systems (ENDS) are crucial to understand their ability to provide an alternative to cigarette smoking. Subjective effects data also strongly contribute to this u
Externí odkaz:
https://doaj.org/article/2772abc927334c4b9c48fdc88134c878
Autor:
Nathan Gale, Mike McEwan, Alison C. Eldridge, Neil Sherwood, Edward Bowen, Simon McDermott, Emma Holmes, Andrew Hedge, Stuart Hossack, Oscar M. Camacho, Graham Errington, John McAughey, James Murphy, Chuan Liu, Christopher J. Proctor, Ian M. Fearon
Publikováno v:
BMC Public Health, Vol 17, Iss 1, Pp 1-18 (2017)
Abstract Background Smoking is a leading cause of numerous human disorders including lung cancer, chronic obstructive pulmonary disease, and atherosclerotic cardiovascular disease. The development of modified risk tobacco products (MRTPs) has been su
Externí odkaz:
https://doaj.org/article/262416f1d095480c9feef5dc6351bd08
Publikováno v:
Drug Testing and Analysis.
Autor:
Ian M. Fearon, Ryan G. N. Seltzer, Trisha L. Houser, Andrew Tope, Xavier Cahours, Thomas Verron, Layla Malt, Thomas Nahde, Grant O'Connell, Mitchell Nides
Publikováno v:
Drug Testing and Analysis.
Publikováno v:
Harm Reduction Journal. 19
Background Nicotine pharmacokinetic assessments of electronic nicotine delivery systems (ENDS) are crucial to understand their ability to provide an alternative to cigarette smoking. Subjective effects data also strongly contribute to this understand
Autor:
Ian M. Fearon, Ryan G. N. Seltzer, Trisha L. Houser, Andrew Tope, Xavier Cahours, Thomas Verron, Layla Malt, Thomas Nahde, Grant O'Connell, Mitchell Nides
Publikováno v:
Drug testing and analysisREFERENCES.
Greater nicotine delivery is associated with higher nicotine concentrations in electronic nicotine delivery system (ENDS) liquids. However, there is a current debate as to whether this leads to increased dependence and mitigates ENDS public health po
Publikováno v:
Drug testing and analysis.
Analysis of the chemical composition of e-cigarette emissions is an important step in determining whether e-cigarettes offer both individual and population-level harm reduction potential. Commonly, e-cigarette emissions for chemical analysis are coll
Publikováno v:
Nicotine & Tobacco Research
Introduction This randomized, open-label, crossover clinical study evaluated nicotine pharmacokinetics (PK) and subjective effects of the JUUL System (JS; Juul Labs, Inc.) with three nicotine concentrations compared to the usual brand (UB) cigarettes